Today’s smart drugs weren’t created for cognitive enhancement. Drugs like modafinil and methylphenidate were created to treat real cognitive disorders. At best, these drugs have questionable effectiveness for enhancement. If the best option for smart drugs are drugs that were never intended for enhancement, when can we expect pharmaceutical companies to develop, test and market real smart drugs for cognitive enhancement?
The main blocker to targeted CED development, at least in the US and EU, are the regulations pharmaceutical companies must operate under. Regulations in these companies generally support the development of drugs to treat deficiencies or, as in the case of drugs like Viagra, restoring function. The development of drugs specifically to enhance a function, like cognition, is unlikely to get support from regulatory bodies. Without that support, there is little value in drugs companies allocating resources in drugs that won’t come to market.
Of course the EU and US aren’t the only regulatory environments. Brazil, China and especially Russia appear to have more lax regimes. CEDs developed there will certainly make their way into other markets, either legitimately or illegitimately. The safety of these drugs, particularly in the form of long-term side effects, will likely remain an open question. An all too likely outcome may look like this:
Brains are complicated
Putting aside the regulatory challenges, is it even possible to create CEDs that are both beneficial and lack side effects? Technologies like fMRI are improving the understanding of the brain, but that’s a long way from effectively influencing brain function.
It’s easy to dismiss how complicated it is to manipulate brain function. Don’t. Many of today’s therapeutic drugs have mechanisms that are only lightly understood. And this is for drugs used to treat deficiencies, when variations from the norm can be detected. There’s still little idea of what levers to pull to enhance already normally functioning brains.
That said, breakthroughs and insights occur regularly. New technologies may surpass what fMRI can tell us; or new substances may greatly improve working memory or executive function with little to no negative side effects. Our own sappho juice may be just around the corner.